![Credit Card 160×600 [EN]](https://dcgreferral.com/wp-content/uploads/2024/05/US-Japan-and-German-April-Consumer-Confidence-Rebound-Orbex.webp.webp)
Similar Posts
How to Become a Day Trader at Home: A Step-by-Step Guide.
How to Become a Day Trader at Home: A Step-by-Step Guide Day trading from the comfort of your home is not only possible but increasingly popular. With the right tools, strategies, and education, anyone with dedication can become a successful day trader. Moreover, this guide will walk you through the essential steps to get started,…
From $500 to $1500 – Our XAUUSD EA Trading Journey (April Update)
Trading isn’t about hype, it’s about consistency and controlled growth. And that’s exactly what this EA is delivering. On April 1st, we began this journey with a $500 account, powered by our EMA + MACD-based Expert Advisor on XAUUSD (M5 timeframe). Performance Snapshot (April 1st – April 17th) ✅ Total Trades Executed: 36 ✅ Execution…
More than 70% of Japanese firms are considering price hikes this fiscal year | Forexlive
Japan inflation indications from a Reuters poll. A growing majority of Japanese companies are preparing to raise prices in the face of rising labour and raw material costs Of the firms polled, 13% said they had already increased prices in the business year that began April 1, while a further 70% said they are considering…
FBS Analysts Expect Market Recovery After Recent Bitcoin Decline
FBS, a leading global broker, presents its latest market analysis exploring the recent Bitcoin downturn and the broader outlook for the cryptocurrency market in 2025. Despite a 28% price drop since the beginning of the year, FBS analysts suggest the current market phase is part of a broader correction and potentially an early stage of…
XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation® technology
Freising, Germany, June 10, 2025 — XL-protein GmbH, a pioneer in the area of biopolymers for pharmacokinetic optimization, announced today that it has entered into a worldwide License, Development and Commercialization Agreement with Grifols, a global healthcare company and leading manufacturer of plasma-derived medicines, for a novel, long-acting biopharmaceutical product. Under this collaboration, XL-protein will…
